: Monitor serum creatinine levels; small increases are common but should be assessed if they persist.

Monitor closely if the patient is also taking warfarin, as dronedarone can increase warfarin exposure. 4. Patient Monitoring

: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III).

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide

: Periodic testing is recommended due to reported cases of liver injury.

It is intended to reduce the risk of hospitalization for AF. 3. Safety and Contraindications

Based on the code , this guide provides a breakdown of the ATHENA clinical trial (A Trial with dronedarone to prevent Hospitalization or death in patients with Atrial fibrillation) and the associated use of dronedarone (brand name Multaq ) for cardiovascular health. 1. Overview of the ATHENA Trial

The official FDA label outlines critical safety measures based on ATHENA data: :